This study reported that plerixafor plus G-CSF compared with placebo plus G-CSF can increase the proportion of older patients significantly who achieved ≥ 2 × 106 CD34+ cells/kg within 4 days of apheresis and versus those patients treated by placebo + G-CSF (NHL: 50.9 vs. 25.4%, p < 0.001; MM: 69.6 vs. 23.7%, p < 0.001). This evidence concerns the gene CSF3 and Miyoshi myopathy.